% | $
Quotes you view appear here for quick access.

Novartis AG Message Board

  • bluecheese4u bluecheese4u Jan 23, 2013 1:41 AM Flag

    Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013

    Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013

    January 23, 2013 07:00 CET

    Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year
    Fourth quarter net sales reached USD 14.8 billion (0%, +2% cc); full year net sales were USD 56.7 billion (-3%, 0% cc)
    Core[1] operating income rose 3% (+5% cc) to USD 3.7 billion in the fourth quarter; for full year, core operating income was USD 15.2 billion (-5%, -2% cc)
    Core EPS was USD 1.27 (+3%, +4% cc) in fourth quarter, USD 5.25 (-6%, -3% cc) in full year
    Free cash flow[1] reached USD 3.5 billion for fourth quarter, USD 11.4 billion for full year
    Dividend of CHF 2.30 per share proposed for 2012; 16th consecutive increase
    Strong momentum from innovation, growth and productivity continues
    17 major approvals in 2012, including Afinitor in advanced breast cancer in the US and EU, Jakavi for myelofibrosis in the EU and Dailies Total1 in the US; Bexsero, our breakthrough meningococcal serogroup B vaccine, received a positive CHMP opinion in the fourth quarter
    Recently launched products grew 13% to USD 16.3 billion or 29% of Group net sales for the full year; Gilenya attained blockbuster status with USD 1.2 billion in full-year sales
    Industry-leading pipeline with over 200 projects in clinical development, including 138 in Pharmaceuticals; over next 2 years, Novartis anticipates 24 pivotal study readouts and up to 20 filings and 18 potential approvals in Pharmaceuticals alone
    Strong progress in quality remediation; Sandoz site in Broomfield, Colorado achieved upgraded compliance status from FDA in fourth quarter
    Proposed changes to Novartis Board of Directors
    Having served in leadership positions as CEO and Chairman of Novartis for 17 years, Dr. Daniel Vasella has decided not to stand for re-election to the Novartis Board of Directors at the company's Annual General Meeting (AGM) on February 22, 2013. Dr. Jörg Reinhardt is proposed as the new Director of Novartis AG and designated non-executive Chairman of the Board of Directors, effective as of August 1, 2013. During the transition period, current Vice-Chairman Prof. Dr. Ulrich Lehner will lead the Board on an ad interim basis
    Dr. Verena Briner, Dr. Charles Sawyers, and Mr. William Winters are also proposed to become members of the Novartis Board of Directors for election at the AGM. As previously announced, Ms. Marjorie Yang has taken the decision not to stand for re-election
    Novartis expects 2013 sales to be in line with 2012 in constant currencies, after absorbing impact of generic competition which could amount to as much as USD 3.5 billion
    2013 core operating income (cc) expected to decline in mid-single digits
    Next growth phase expected to begin in 2013, resulting in 2014 and 2015 expected reported sales growth of at least mid-single digits, with core operating income growing ahead of sales


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • NVS Chart

      Analyst Estimates

79.31-0.24(-0.30%)4:02 PMEDT